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The use of probiotics in the prevention or treatment of some vaginal infections has been the subject of numerous studies. To assess
the presence of Lactobacillus casei rhamnosus (LCR35) in the vagina after an oral administration, an open randomised pilot study
was conducted on 20 healthy women of child-bearing age. Materials and Methods. 2 groups of 10 women were given a 28-day oral
course, that is, at least 108CFU/day (group 1) or 2 × 108CFU/day (group 2) of LCR35. Nugent score and vaginal screening for
LCR35 were undertaken before and after 28 days of treatment. Results. The mean Nugent score decreased in group 1 (−0,2) as well
as in group 2 (−0,3). 10% of women in group 1 versus 40% of women in group 2 were carrying LCR35 at the end of the trial.
Conclusion. LCR35, at the minimal dose of 2 × 108CFU/day, can return the Nugent score to normal in healthy women of child-
bearing age, by means of a well-tolerated vaginal temporary presence. Phase III clinical trials will specify the preventive or curative
impact of this orally administered strain on a range of vaginal disorders such as bacterial vaginosis or vulvovaginal candidiasis.
1.Introduction
Lactobacilli play a fundamental role in the ecological balance
of the vagina. Many vaginal infections result from the
disappearance or the quantitative or qualitative decrease in
lactobacilli naturally present in the vagina. This is partic-
ularly true with bacterial vaginosis (BV), one of the most
common vaginal infections estimated to have a prevalence
between 15% and 30% [1].
Over the last few years, studies have been conducted
to assess the usefulness of probiotics to treat or prevent
vaginal infections such as BV or vaginal candidiasis. The
clinicalresultsdiﬀerwidelybecauseoftherangeofprobiotics
used, the routes of administration of probiotics (oral or
vaginal), the duration of treatment and the cohorts studied.
Among the points requiring clariﬁcation are the type of
lactobacilli used in the probiotic preparations and the route
of administration (oral or vaginal).
Lactobacillus casei rhamnosus LCR35 (LCR35) has shown
in vitro that it has the required characteristics for vaginal
colonization [2]:
(i) proven fast adherence (one hour) to the vaginal wall,
and
(ii) prevention of growth of potential pathogens such as
Prevotella bivia, Gardnerella vaginalis, and Candida
albicans from the 4th hour after incubation [2].
About the route of administration, an oral preparation
seems to be interesting since studies have shown that the
rectum was the natural reservoir for commensal vaginal
lactobacilli [3, 4].
An open pilot study was conducted in healthy women to
assess the eﬃcacy and safety of this route of administration
for LCR35.
2.MaterialandMethods
An open randomised trial was conducted on 20 healthy
women to assess the vaginal impact of the daily oral
administration of two diﬀerent doses of LCR35 for 28 days.
T h ep r o t o c o lw a ss u b m i t t e dt ot h eA g e n c eF r a n c ¸aise de
S´ ecurit´ e Sanitaire des Produits de Sant´ e (AFSSaPS) and the2 Infectious Diseases in Obstetrics and Gynecology
EthicsCommittee(Comit´ edeProtectiondesPersonnes,CPP
Ile de France VII) who, respectively, issued an authorisation
and a favourable opinion.
2.1. Study Cohort and Trial Design. This single-centre trial
(Institute Alfred Fournier, Paris) included 20 healthy women
who were randomized into two groups of ten women each.
At the screening visit, inclusion criteria were women
between 18 and 45 years old, premenopausal, nonpregnant,
using eﬀective contraception (i.e., all kind of contraception
(hormonal, IUD, chemical, condoms) except “natural con-
traception” like co¨ ıtus interrompus), not taking any anti-
infectious treatment and not immunodeﬁcient.
Allpatientswereaskedforgenitalsymptomsofinfections
(abnormaldischarge,pruritus,burning,ordyspareuniaetc.).
Symptomatic patients were excluded.
The simple practical technique of self-sampling was
chosen because studies demonstrated that self-collected
samples had the same microbiological diversity as physician-
collected samples [5, 6]. All the women took a sample from
their own vagina at the inclusion visit using two sterile
cotton swabs mounted on a wooden handle (Deltalab) and
introduced over a distance of 2 to 3 cms into the vagina. One
swab was used to determine the Nugent score [7]. The other
swab was placed in a survival medium (FT-MRS) and frozen
for LCR35 screening.
During the screening visit, all the women received an
information leaﬂet on the study and all signed an informed
consent form.
Three to seven days later, women were included, ran-
domised in two groups, and given the treatment.
(i) Group 1 (10 women): 1 gel capsule of LCR35 per os
per day (i.e., a minimum of 108 CFU) for 28 days.
(ii) Group 2 (10 women): 2 gel capsules of LCR35 per os
perday(i.e.,aminimumof2 ×108 CFU)for28days.
The period of 28 days for the control visit has been
chosen to sample vaginal secretions at the same time of the
menstrual cycle.
2.2. Microbiological Methods
2.2.1.NugentScore. Afterspreadingthevaginalsecretionson
a slide and colouring with the Gram technique, the score was
used to classify the vaginal microbiota in three categories:
normal(0to3),intermediate(4to6),andbacterialvaginosis
(7 to 10).
2.2.2. LCR35 Identiﬁcation. At days D7 and D30, immedi-
ately after sampling, vaginal swabs were homogenised in
FT-MRS, then the solution was divided into 6 cryotubes
(containing 33% ﬁnal glycerol). The divided fractions were
then stored at −80◦C before analysis [(1) to (3)].
(1) Culture. After thawing at 37◦C ,af r a c t i o nw a su s e d
to establish a diluted series at 1/10th (up to a dilution of
−7). Cultures were done on MRS, Rogosa and DP media.
The Rogosa, and DP media were incubated in anaerobic
conditions for 72h at 37◦C and the MRS medium was
incubated in both aerobic and anaerobic conditions for 72h
at37◦C.Theculturesweredoneinduplicateforthepurposes
of statistical analysis.
(2) REP-PCR. After culture on MRS for 72h at 37◦Ci n
aerobic conditions, 10 colonies per sample were taken and
the REP-PCR proﬁle of each one was performed. The colony
was lysed by heat shock directly in the thermocycler on
the basis of previous tests carried out in our laboratory
(data not shown). The DNA of each of the 10 colonies was
ampliﬁed in a reagent medium containing MgCl buﬀer2
1X (MPbiomedicals), 0.2mM of DNTP (MPbiomedicals),
0.5µM of primer (GTG)5,1 . 5 m Mo fM g C l 2 (MPbiomed-
icals), 2.5 units of Taq polymerase (MPbiomedicals) with
sterile water added to make 50µL. The ampliﬁcation
cycle is as follows: 5min/94◦C; (30s/94◦C; 1min/45◦C;
2min/72◦C)×29 cycles; 7min/72◦C; Hold 10◦C. The result
of ampliﬁcation is visible on 1.5% agarose gel, supplemented
with 10% B.E.T, following migration for 52min at 75 volts.
(3) Speciﬁc PCR. The total DNA of a fraction from a sample
is extracted according to supplier recommendations with
the QIAamp MiniKit for stool (QIAGEN). Ampliﬁcation
of a speciﬁc region of strain LCR35 was done using hyb
21 primers [8]. The adjustment of this technique enabled
us to obtain an ampliﬁcation of LCR35 at a hybridization
temperature of 56◦C, in a mix made up of 3mM of MgCl2,
2U of Taq polymerase (QBiogen), 0.2mM of each dNTP,
0 . 5 m Mo fp r i m e r sa n d1 Xo fT a qb u ﬀer (Qbiogen). The
DNA is ampliﬁed using successive cycles of: (94◦C, 5min,
(94◦C, 30s; 56◦C, 30s; 72◦C, 1min/kb) × 25–35, 72◦C,
7min). The ampliﬁed fragments were then deposited on 2%
agarose gel before migration at 100V for 30min.
2.3. Eﬃcacy and Safety Criteria
2.3.1. Vaginal Criteria. The vaginal impact of the oral
treatment was evaluated on the following.
(i) Assessment of the Nugent scores on inclusion and at
the end of the trial.
(ii) PCR screening for LCR35 in the vagina at the end of
treatment.
2.3.2. Safety. Patients were told to note any adverse event
(local or general) during the study and to consult their
physicianifnecessary.Atthecontrolvisit,thephysicianasked
the patients about genital or general symptoms and taken
medications during the study.
3. Results
The mean age of women included was 27.2 ± 6.8 years.
No signiﬁcant diﬀerence was noted as regards demographic
characteristics (age, weight, height, BMI, urinary pregnancy
test) between groups 1 and 2.Infectious Diseases in Obstetrics and Gynecology 3
Table 1: Changes in Nugent scores.
Nugent score
Group 1 (n = 10) Group 2 (n = 10)
V1 V3 V1 V3
Normal (0 to 3) 8 (80%) 9 (90%) 10 (100%) 10 (100%)
Intermediate (4 to 6) 1 (10%) 1 (10%) — —
Bacterial vaginosis
(7 to 10) 1 (10%) — — —
All the women in group 1 took their treatment in
accordance with the protocol. 1 patient in group 2 missed
1 day of treatment but nevertheless took all the capsules.
3.1. Vaginal Criteria (Table 1)
3.1.1. Group 1 (at Least 108 CFU of LCR35 per Os per Day).
Before treatment, the mean Nugent score for group 1 was
1.8:8 women had normal microbiota, 1 had intermediate
microbiota, and 1 had BV (asymptomatic patient).
After treatment, the mean score for group 1 was 1.6:9
women had normal microbiota, 1 had intermediate micro-
biota. Note that the patient with microbiological BV on
inclusion had normal microbiota by the end of the trial. At
the end of the trial, LCR35 had been revealed in the vaginal
microbiota of one out of 10 women (10%) in this group.
3.1.2.Group2(atLeast2 ×108 CFUofLCR35perosperDay).
Before treatment, the mean Nugent score was 1 (10 women
with normal microbiota).
After treatment, the mean Nugent score was 0.7 (10
women with normal microbiota).
At the end of the trial, LCR35 had been revealed in the
vaginal microbiota of four out of 10 women (40%) in this
group.
Nugent score decreased in both groups but slightly more
signiﬁcantly in group 2 despite a lower score at inclusion
(resp., −0.3 versus −0.2).
At the end of the trial, LCR35 was revealed in the vaginal
microbiota of 5 out of 20 women (25%).
3.2. Safety. No side eﬀects and no withdrawal of treatment
were reported either by patients or by physician during the
trial involving 20 women.
4. Discussion
One of the exclusion criteria was postmenopausal women,
which led to an age group between 18 and 45years old. After
menopause, the lack of oestrogen causes a change in the
vaginal ecosystem, with a signiﬁcant decrease in the number
of lactobacilli [9, 10]. The inclusion of postmenopausal
women would therefore have introduced bias into the trial.
The exclusion of women with clinical signs of vaginal
infection is justiﬁed for ethical reasons. It would have been
controversial not to start speciﬁc treatment of the infection
and this, again, would have introduced a bias into the trial.
On the other hand, the patient with asymptomatic BV
was not excluded because there was no risk of complications
(as this patient was not pregnant). Treatment of the infection
couldthereforebepostponed,especiallyintheabsenceofany
clinical symptoms.
The two bacteriological samples were taken at an interval
of four weeks to ensure that the women were at the same
point in their cycle or in the taking of contraception, that
is, under the same conditions of hormonal impregnation as
studies [11, 12] demonstrated slight changes in lactobacillus
microbiota during the menstrual cycle.
The Nugent score has been used for this trial because,
even if it is an imperfect test, it stays the benchmark score
[5] used to evaluate the quality of the vaginal microbiota
and the load of lactobacilli in a semiquantitative manner.
It is based on a direct examination after colouring of the
vaginal secretions. The examination has been standardised
but remains observer-dependent. During this trial, all the
Nugent tests were conducted in the same microbiology
laboratory (Institute Fournier, Paris) by the same observer.
At the end of treatment, LCR35 was identiﬁed, by REP-
PCR, four times more often (resp,. 40% versus 10% of
women) among women in group 2 (at least 2 capsules dosed
at 108 CFU of LCR35/day) than among the women in group
1 (at least 1 capsule dosed at 108 CFU of LCR35/day). The
daily dose of LCR35 therefore played a signiﬁcant role in the
vaginal uptake of the probiotic.
19 of the 20 treated women had a normal Nugent
score at the end of the study (Table 1); one woman had an
intermediate score. Note that the patient with asymptomatic
BV at inclusion (Nugent score ≥ 7) returned to a normal
Nugent score at the end of the study. Thus overall, the
treatment improved the Nugent scores, particularly at the
dose of 2 × 108 CFU of LCR35/day.
Few studies have been conducted on the vaginal uptake
of lactobacilli following an oral dose of probiotics. Reid
et al. [13] randomised 42 healthy women (mean age 31
years) into 3 groups: 8.108 or 6.109 or 2 × 8.108 of a
combinationofL.rhamnosusGR-1+L.fermentumRC-14for
28 days. A change to normal vaginal microbiota (appreciated
semiquantitatively by the Nugent score) was signiﬁcant only
at a dose of 1.6·109 GR-1/RC-14, showing the potential
ability of oral probiotics to restore or maintain a normal
vaginal ecosystem.
The same author published in 2003 [14] an other study
about 64 healthy women who received either an oral dose
of L. rhamnosus + L. reuteri or an oral dose of placebo for
60 days. A microbiological examination showed a signiﬁcant
rise in the level of vaginal lactobacilli at D28 and D60 in the
probiotic group compared to the placebo group. However, in
that study, there was no PCR identiﬁcation of the strains of
v a g i n a ll a c t o b a c i l l ib e f o r eo ra f t e rt r e a t m e n t .
Morelli [15] administrated L. rhamnosus GR-I + L.
fermentum RC-14 for 14 days per os to a group of 10 women.
A vaginal colonisation was identiﬁed by REP-PCR between
0% and 60% depending on the observation period after the
oral administration.
The results of our study of LCR35 therefore agree with
the results of other studies using other strains of lactobacilli.4 Infectious Diseases in Obstetrics and Gynecology
Finally, the literature on probiotics reports an improve-
ment in general immunity [16–18] when taking probiotics,
mainly resulting from indirect eﬀects:
(i) increased migration of immune cells (macrophages,
lymphocytes, etc.);
(ii) increased phagocytosis;
(iii) Production of proinﬂammatory cytokines, and so
forth.
The same type of result was shown in children with
LCR35 [19].
5. Conclusion
This randomised trial is the ﬁrst formal demonstration of
the positive impact of the oral administration of LCR35
on vaginal microbiota. Treatment with a daily dose of 2
gel capsules LCR35 per os produced an overall decrease
in the Nugent score in healthy women and, therefore, the
maintenance of the quality of their vaginal microbiota.
A return to normal was even observed in one case of
asymptomatic BV. Our work also demonstrated, by using
REP-PCR, LCR35’s ability to be temporarily present in the
vagina after 28 days oral treatment without generating any
adverse events. This means that the probiotic is able to
survive through the gastric tract before being temporarily
present in the vaginal area. Note that the vaginal impact of
LCR35 appears to be dose-dependent since, after treatment,
we observed that 40% of women who received at least 2
capsules dosed at 108 CFU/day of LCR35 were carrying
LCR35, compared to only 10% of women in the group that
received at least one capsule dosed at 108 CFU/day.
This shows that, at a dose of 2 × 108 CFU/day, LCR35 is
able to restore or maintain a normal vaginal microbiota in
healthy premenopausal women, with a high level of safety
and compliance with treatment.
New clinical trials are now required to specify the
preventive or curative impact of this strain, administered
orally, in the treatment of various vaginal diseases such as
BV or vulvovaginal candidiasis.
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